The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Nasal sprays are available by prescription or over the counter (OTC). Most products come in a hand-operated pump bottle or squeeze bottle. Knowing how to use a nasal spray is important ...

Padagis®, a leading generic manufacturer, announced today it is lowering the price of its over-the-counter (OTC) 4 mg ...

(www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...